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BACKGROUND Paravalvular regurgitation (PVR) has been associated
with adverse outcomes. Balloon post-dilation is an effective strategy
to treat PVR in case of frame under-expansion. We evaluated the
impact of device sizing and aortic valve calciﬁcation distribution on
paravalvular regurgitation and the need for post-dilation after trans-
catheter aortic valve replacement (TAVR) with the self-expanding
CoreValve prosthesis (Medtronic Inc., Minneapolis, MN).
METHODS We conducted a multicenter study, which included 183
consecutive patients undergoing CoreValve implantation with pre-
procedural multidetector computed tomography (MDCT). Quantita-
tive assessment of aortic root dimensions and calcium volume for
leaﬂet and left ventricular outﬂow tract (LVOT) were retrospectively
performed with MDCT in a centralized core laboratory.
RESULTS Moderate or severe PVR was reported in 27 patients (14.8%),
and post-dilation was performed in 58 patients (31.7%). Multivariable
analysis found perimeter oversizing (odds ratio [OR] 0.90; 95% con-
ﬁdence interval [CI]: 0.83 – 0.98; p ¼ 0.01) and leaﬂet calcium volume
(per increase of 100 mm3, OR 1.18; 95% CI: 1.06 – 1.31; p ¼ 0.002) as
independent predictors of signiﬁcant PVR with cutoff values of 13.6%
and 583 mm3, respectively. In terms of the need for post-dilation,
LVOT calciﬁcation was identiﬁed as independent predictor (OR 2.23;
95% CI: 1.09 – 4.58; p ¼ 0.028) as well as perimeter oversizing (OR
0.93; 95% CI: 0.88 – 0.99; p ¼ 0.015) and leaﬂet calcium volume (per
increase of 100mm3, OR 1.17; 95% CI: 1.05 – 1.31; p ¼ 0.004).
Comparing to the manufacture’s recommendation for prosthesis
sizing, satisfying cutoff value of perimeter oversizing (13.6%) would
reduce incidence of signiﬁcant PVR (7.1% vs. 33.3%; p < 0.001) and the
need for post-dilation (21.6% vs. 46.7%; p ¼ 0.011).
Multivariate Predictors of Signiﬁcant Paravalvular RegurgitationParametersUnivariate
analysis
OR (95% CI) p valueMultivariate
analysis
OR (95% CI) p valueFemale 0.41 (0.17 - 0.99) 0.048Body mass index 0.88 (0.78 - 0.99) 0.04Annulus
perimeter1.11 (1.04 - 1.18) 0.001Perimeter
oversizing0.86 (0.80 -
0.93)< 0.001 0.90 (0.83 -
0.98)0.01Leaﬂet calcium
volume per
increase of
100 mm31.24 (1.12 - 1.36) < 0.001 1.18 (1.06 - 1.31) 0.002CI ¼ conﬁdence interval; OR ¼ odds ratio
CONCLUSIONS Perimeter oversizing and leaﬂet calciﬁcation pre-
dicted signiﬁcant PVR after self-expanding TAVR. To avoid signiﬁcant
PVR, optimal device sizing and adequate post-dilation should be in-
tegrated into treatment strategy.CATEGORIES STRUCTURAL: Valvular Disease: Aortic
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BACKGROUND Patients with severe aortic valve stenosis undergoing
transcatheter aortic valve implantation (TAVI) have elevated NT-
proBNP values. There seems to be a correlation between the increased
value of this protein with the severity of the valvular stenosis,
although its meaning after TAVI is not well established. We aim to
analyze its prognostic value in our TAVI population.
METHODS Single center study of 193 prospectively included TAVI
patients admitted to our Cath lab (VCROSS registry), during a period of
6 years (5 patients were excluded due to peri-procedural death). The
primary objective was to assess the impact of pre and post-procedural
NT-proBNP in the prediction of 1-year mortality.
RESULTS 188 patients with a mean age of 81 (þ-7.7) years, 55.3% fe-
male, median STS mortality score of 5.1%(IQR 3.5-7.1), 10.1% with
LVEF <35%, median pre-procedure NT-proBNP of 2405 (IQR 1230-
7790) and post NT-proBNP 2190 ng/l (IQR 806-5485). There wasn’t a
signiﬁcant early post-procedural reduction of NT-proBNP levels
(p¼0.220). At one year there were 23 deaths (12.2%). Patients with
LVEF <35% had higher rates of mortality (36.8% vs.9.5%, p¼0.001), as
did patients with liver failure (50.0% vs. 11.4%, p¼0.020). Mortality at
one year was also signiﬁcantly related to higher STS scores (6.7% (IQR
4.65-10.73) in patients who died vs 5.1%(IQR 3.6-7-17), p¼0.039). NT-
proBNP value that better discriminated one year mortality was
2520ng/l. Levels above this cutoff were related to a higher mortality
(21.5% vs. 3.9%, p¼0.001). Multivariate Cox regression model revealed
that post procedural NT-proBNP >2520ng/l is the only independent
predictor of mortality (HR 6.27, CI 95%, 1,801-21,866, p¼0.004).
CONCLUSIONS Post-procedural NT-proBNP is an independent pre-
dictor of 1-year mortality and stratiﬁes a population at higher risk of
death. Pre and post TAVI levels of NT-proBNP help in the selection
and management of these patients.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is
well-established treatment for failing bioprosthetic valves in patients
at high-risk for conventional heart surgery. Elderly patients with
degenerated bioprostheses and signiﬁcant comorbidities are a sub-
group in which TAVI represents a viable option. However, small bio-
prostheses with outer diameter of 19-21 mm are frequently used in
these patients, representing a challenge for currently available
transcatheter valves, with a potential risk of residual transvalvular
gradient or regurgitation due to inadequate leaﬂet coaptation. The
new Medtronic CoreValve Evolut R provides several reﬁnements to
improve anatomical ﬁt, annular sealing, and durability. Moreover, the
